Clinical Trial: Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT04712877) titled 'Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers' on Oct. 16, 2020.

Brief Summary: This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected early stage lung cancers scheduled to undergo biopsies to establish the diagnosis of lung cancer.

The primary purpose of this testing is to determine the presence of 10 oncogenic drivers (mutati...